366 related articles for article (PubMed ID: 33051339)
1. Role of myeloid-derived suppressor cells in the promotion and immunotherapy of colitis-associated cancer.
Wang Y; Ding Y; Deng Y; Zheng Y; Wang S
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33051339
[TBL] [Abstract][Full Text] [Related]
2. Blockade of Myd88 signaling by a novel MyD88 inhibitor prevents colitis-associated colorectal cancer development by impairing myeloid-derived suppressor cells.
Wang L; Hu D; Xie B; Xie L
Invest New Drugs; 2022 Jun; 40(3):506-518. PubMed ID: 35089465
[TBL] [Abstract][Full Text] [Related]
3. G-MDSC-derived exosomes mediate the differentiation of M-MDSC into M2 macrophages promoting colitis-to-cancer transition.
Wang Y; Liu H; Zhang Z; Bian D; Shao K; Wang S; Ding Y
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37364932
[TBL] [Abstract][Full Text] [Related]
4. Hydrogen Sulfide Reduces Myeloid-Derived Suppressor Cell-Mediated Inflammatory Response in a Model of
De Cicco P; Sanders T; Cirino G; Maloy KJ; Ianaro A
Front Immunol; 2018; 9():499. PubMed ID: 29636751
[TBL] [Abstract][Full Text] [Related]
5. Dioscin modulates macrophages polarization and MDSCs differentiation to inhibit tumorigenesis of colitis-associated colorectal cancer.
Xun J; Zhou S; Lv Z; Wang B; Luo H; Zhang L; Yang L; Zhang A; Wu X; Wang Z; Wang X; Yu X; Zhang Q
Int Immunopharmacol; 2023 Apr; 117():109839. PubMed ID: 36809720
[TBL] [Abstract][Full Text] [Related]
6. MDSCs are involved in the protumorigenic potentials of GM-CSF in colitis-associated cancer.
Ma N; Liu Q; Hou L; Wang Y; Liu Z
Int J Immunopathol Pharmacol; 2017 Jun; 30(2):152-162. PubMed ID: 28534709
[TBL] [Abstract][Full Text] [Related]
7. Targeting Myeloid-Derived Suppressor Cells in Cancer.
Anani W; Shurin MR
Adv Exp Med Biol; 2017; 1036():105-128. PubMed ID: 29275468
[TBL] [Abstract][Full Text] [Related]
8. Aberrant function of myeloid-derived suppressor cells (MDSCs) in experimental colitis and in inflammatory bowel disease (IBD) immune responses.
Kontaki E; Boumpas DT; Tzardi M; Mouzas IA; Papadakis KA; Verginis P
Autoimmunity; 2017 May; 50(3):170-181. PubMed ID: 28276713
[TBL] [Abstract][Full Text] [Related]
9. Glycolysis regulates the expansion of myeloid-derived suppressor cells in tumor-bearing hosts through prevention of ROS-mediated apoptosis.
Jian SL; Chen WW; Su YC; Su YW; Chuang TH; Hsu SC; Huang LR
Cell Death Dis; 2017 May; 8(5):e2779. PubMed ID: 28492541
[TBL] [Abstract][Full Text] [Related]
10. Immunosuppressive Effects of Myeloid-Derived Suppressor Cells in Cancer and Immunotherapy.
Krishnamoorthy M; Gerhardt L; Maleki Vareki S
Cells; 2021 May; 10(5):. PubMed ID: 34065010
[TBL] [Abstract][Full Text] [Related]
11. The role of myeloid-derived suppressor cells in the pathogenesis of rheumatoid arthritis; anti- or pro-inflammatory cells?
Rajabinejad M; Salari F; Gorgin Karaji A; Rezaiemanesh A
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):4149-4158. PubMed ID: 31698956
[TBL] [Abstract][Full Text] [Related]
12. Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer.
Law AMK; Valdes-Mora F; Gallego-Ortega D
Cells; 2020 Feb; 9(3):. PubMed ID: 32121014
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy Targeting Myeloid-Derived Suppressor Cells (MDSCs) in Tumor Microenvironment.
Gao X; Sui H; Zhao S; Gao X; Su Y; Qu P
Front Immunol; 2020; 11():585214. PubMed ID: 33613512
[TBL] [Abstract][Full Text] [Related]
14. STAT1 Is Required for Decreasing Accumulation of Granulocytic Cells via IL-17 during Initial Steps of Colitis-Associated Cancer.
Delgado-Ramirez Y; Baltazar-Perez I; Martinez Y; Callejas BE; Medina-Andrade I; Olguín JE; Delgado-Buenrostro NL; Chirino YI; Terrazas LI; Leon-Cabrera S
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299314
[TBL] [Abstract][Full Text] [Related]
15. Nanoparticle Systems Modulating Myeloid-Derived Suppressor Cells for Cancer Immunotherapy.
Wilkerson A; Kim J; Huang AY; Zhang M
Curr Top Med Chem; 2017; 17(16):1843-1857. PubMed ID: 27875974
[TBL] [Abstract][Full Text] [Related]
16. Suppressive role of myeloid-derived suppressor cells (MDSCs) in the microenvironment of breast cancer and targeted immunotherapies.
Shou D; Wen L; Song Z; Yin J; Sun Q; Gong W
Oncotarget; 2016 Sep; 7(39):64505-64511. PubMed ID: 27542274
[TBL] [Abstract][Full Text] [Related]
17. Role played by MDSC in colitis-associated colorectal cancer and potential therapeutic strategies.
Wang K; Wang Y; Yin K
J Cancer Res Clin Oncol; 2024 May; 150(5):243. PubMed ID: 38717677
[TBL] [Abstract][Full Text] [Related]
18. Myeloid-derived suppressor cells-a new therapeutic target to overcome resistance to cancer immunotherapy.
Chesney JA; Mitchell RA; Yaddanapudi K
J Leukoc Biol; 2017 Sep; 102(3):727-740. PubMed ID: 28546500
[TBL] [Abstract][Full Text] [Related]
19. Myeloid-Derived Suppressor Cells in Prostate Cancer: Present Knowledge and Future Perspectives.
Koinis F; Xagara A; Chantzara E; Leontopoulou V; Aidarinis C; Kotsakis A
Cells; 2021 Dec; 11(1):. PubMed ID: 35011582
[TBL] [Abstract][Full Text] [Related]
20. Myeloid-Derived Suppressor Cells in Sepsis.
Schrijver IT; Théroude C; Roger T
Front Immunol; 2019; 10():327. PubMed ID: 30873175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
